Lyvispah Granule
NDC Package 87519-003-90

11-digit billing NDC: 87519000390
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Lyvispah (baclofen) granules is baclofen is used to treat muscle spasms caused by certain conditions (such as multiple sclerosis, spinal cord injury/disease). This formulation utilizes a granule delivery system. Marketed by Anvi Pharmaceuticals Inc, this product is identified by NDC 87519-003 and is authorized under FDA application NDA215422.

Identification & Billing

NDC Package Code
87519-003-90
Package Description
90 PACKET in 1 CARTON / 1 GRANULE in 1 PACKET
Product Code
87519-003
11-Digit Billing Format
87519000390

Clinical Specifications

Proprietary Name
Lyvispah
Non-Proprietary Name
Baclofen
Substance Name
Baclofen
Dosage Form
Granule - A small particle or grain.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
BACLOFEN 10 mg/1
Pharmacologic Class
Usage Information
Baclofen is used to treat muscle spasms caused by certain conditions (such as multiple sclerosis, spinal cord injury/disease). It works by helping to relax the muscles.

Regulatory & Marketing

Labeler Name
Anvi Pharmaceuticals Inc
Product Type
Human Prescription Drug
FDA Application #
NDA215422
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
09-01-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 87519-003-90 identifies a specific commercial package of 90 packet in 1 carton / 1 granule in 1 packet of Lyvispah, a human prescription drug labeled by Anvi Pharmaceuticals Inc. This granule is formulated for oral use and contains baclofen as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Anvi Pharmaceuticals Inc on September 01, 2026. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Baclofen is used to treat muscle spasms caused by certain conditions (such as multiple sclerosis, spinal cord injury/disease). It works by helping to relax the muscles.

How is this Anvi Pharmaceuticals Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 87519000390. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
87519-003-90
11-Digit CMS (5-4-2)
87519-0003-90

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.